Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Jiankang Yuan was selected for the CSI Public Health Thematic Index, and its investment value has been widely recognized by the market.
Published Time：
2020-07-10
The Shanghai Stock Exchange and the China Securities Index Co., Ltd. officially released the CSI Public Health Theme Index, the CSI Shanghai-Hong Kong-Shenzhen Mainland New Infrastructure Construction Theme Index, and the SSE New Infrastructure Construction Theme Index on July 7, 2020. Joincare Pharmaceutical Group Industry Co., Ltd. (hereinafter referred to as "Health Yuan") was selected as one of the constituent stocks of the CSI Public Health Theme Index due to its outstanding performance in public health environmental governance.
It is understood that the CSI Public Health Theme Index selects listed company securities from the Shanghai and Shenzhen markets whose businesses involve infectious disease prevention and control, medical equipment and medical protective consumables, medical informatization construction, and public health environmental governance as index samples to reflect the overall performance of listed company securities in the public health theme.
Secondly, China's aging society trend has already formed, and it is difficult to change in a short period of time. The CSI Public Health Theme Index conforms to the direction of China's future economic transformation and has high long-term growth potential. From the industry distribution of the market capitalization of the constituent stocks, most of the sample stocks benefit from the pharmaceutical and biotechnology fields related to infectious disease prevention and control: antibiotics, antiviral drugs, vaccines, diagnostic reagents, genetic engineering, blood products, etc.
After years of operation and development, Health Yuan has a diversified and multi-layered R&D institution, and has strong R&D capabilities and international R&D concepts in the fields of chemical and Chinese medicine preparations, biological drugs, diagnostic reagents, health products and food, etc. The product line layout around antimicrobials, anti-tumor, gonadotropins, digestion, nervous system and respiratory system has formed a relatively clear product R&D pipeline. By actively introducing domestic and foreign senior experts and innovative talents, increasing R&D investment, and overseas strategic alliances, the company's R&D competitiveness has been further enhanced. In addition, with the successful launch of two inhalers in 2019, Health Yuan has received continuous attention from many investors.
Public information shows that Health Yuan has been included in the CSI 500 Index, SSE 380, and CSI 800 Index, among other important index constituent stocks. These indexes are representative, authoritative, and widely used in the current A-share market, and can comprehensively reflect the overview and operation of the Chinese securities market, providing a benchmark for investor evaluation and decision-making and related financial derivatives.
It is understood that 2020 is a key year for Health Yuan's transformation and deepening. The company will seize the rare strategic opportunity of technological innovation, continuously promote the continuous improvement of pharmaceutical R&D capabilities, establish high-threshold, barrier-leading medical technology capabilities, serve national interests and people's livelihood, and care for public health. As of press time, its stock price has broken through the 16 yuan mark, but based on the current low valuation of the stock, from the perspective of long-term investment value, many securities firms have continued to be optimistic about the development prospects of Health Yuan.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.